Cargando…

Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument

BACKGROUND: A pilot study conducted in 2020 suggested that Medical Affairs Pharmaceutical Physicians (MAPPs) may be inherently undervalued within the pharmaceutical industry and vulnerable to replacement by less qualified roles. There are currently no standardized metrics to measure MAPP performance...

Descripción completa

Detalles Bibliográficos
Autor principal: Jandhyala, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818008/
https://www.ncbi.nlm.nih.gov/pubmed/34994965
http://dx.doi.org/10.1007/s40290-021-00413-9
_version_ 1784645750683074560
author Jandhyala, Ravi
author_facet Jandhyala, Ravi
author_sort Jandhyala, Ravi
collection PubMed
description BACKGROUND: A pilot study conducted in 2020 suggested that Medical Affairs Pharmaceutical Physicians (MAPPs) may be inherently undervalued within the pharmaceutical industry and vulnerable to replacement by less qualified roles. There are currently no standardized metrics to measure MAPP performance, thus it is necessary to measure the value of MAPPs to employers and clarify the need for their specific skills. OBJECTIVES: The first aim of this study was to identify a list of indicators to produce an MAPP value measurement tool, and the second aim was to determine its discriminant validity by showing that the ‘MAPPval instrument’ differentiated the MAPP role from other internal stakeholders (regulatory affairs, market access, commercial, and patient advocacy) in terms of accountability for pharmaceutical company activities and level of engagement with external stakeholders. METHODS: MAPPs were recruited using convenience sampling via professional networks and completed a qualitative online survey to identify a list of key role indicators using a consensus method known as the Jandhyala method. Responses were coded and scored, and aggregated responses were presented to participants in a Consensus Round. Participants rated their agreement with each item on a 5-point Likert scale, from strongly agree to strongly disagree. Indicators that reached a consensus index of > 50% (CI ≥ 0.51) were retained in the final MAPP performance instrument. Participants’ retrospectively self-reported professional activities over a period of 12 months were used to validate the measure. A two-proportion z-test and Mann–Whitney tests were used to determine discriminant validity by showing whether the value of the MAPP role as defined by the instrument was significantly different from that of other internal stakeholders in terms of their accountability for and external stakeholder benefit from each MAPP activity. RESULTS: In total, 11 MAPPs participated in the Jandhyala method, which generated 22 unique MAPP value indicators. Payor-targeted activities and journal publications had the two highest awareness indexes (1.00 and 0.98, respectively). The retrospective study confirmed the MAPPval instrument’s validity. MAPPs were the only internal stakeholder classified as accountable for at least one activity that benefited all four stakeholders. They were classified as accountable for activities that influenced significantly more external stakeholders than other internal stakeholders, even when activities influenced fewer than four external stakeholders. MAPPs were also accountable for significantly more activities recorded over the 12-month period than regulatory affairs, market access, commercial, and patient advocacy. CONCLUSIONS: This study generated and validated the first measure of MAPP value to pharmaceutical companies. MAPPs have unique value to pharmaceutical companies compared with other roles in terms of their accountability for activities that influence regulators, payors, prescribers, and patients. Through their accountability for pharmaceutical company activities and influence of external stakeholders, MAPPs play a key role in medicine adoption. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40290-021-00413-9.
format Online
Article
Text
id pubmed-8818008
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88180082022-02-23 Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument Jandhyala, Ravi Pharmaceut Med Original Research Article BACKGROUND: A pilot study conducted in 2020 suggested that Medical Affairs Pharmaceutical Physicians (MAPPs) may be inherently undervalued within the pharmaceutical industry and vulnerable to replacement by less qualified roles. There are currently no standardized metrics to measure MAPP performance, thus it is necessary to measure the value of MAPPs to employers and clarify the need for their specific skills. OBJECTIVES: The first aim of this study was to identify a list of indicators to produce an MAPP value measurement tool, and the second aim was to determine its discriminant validity by showing that the ‘MAPPval instrument’ differentiated the MAPP role from other internal stakeholders (regulatory affairs, market access, commercial, and patient advocacy) in terms of accountability for pharmaceutical company activities and level of engagement with external stakeholders. METHODS: MAPPs were recruited using convenience sampling via professional networks and completed a qualitative online survey to identify a list of key role indicators using a consensus method known as the Jandhyala method. Responses were coded and scored, and aggregated responses were presented to participants in a Consensus Round. Participants rated their agreement with each item on a 5-point Likert scale, from strongly agree to strongly disagree. Indicators that reached a consensus index of > 50% (CI ≥ 0.51) were retained in the final MAPP performance instrument. Participants’ retrospectively self-reported professional activities over a period of 12 months were used to validate the measure. A two-proportion z-test and Mann–Whitney tests were used to determine discriminant validity by showing whether the value of the MAPP role as defined by the instrument was significantly different from that of other internal stakeholders in terms of their accountability for and external stakeholder benefit from each MAPP activity. RESULTS: In total, 11 MAPPs participated in the Jandhyala method, which generated 22 unique MAPP value indicators. Payor-targeted activities and journal publications had the two highest awareness indexes (1.00 and 0.98, respectively). The retrospective study confirmed the MAPPval instrument’s validity. MAPPs were the only internal stakeholder classified as accountable for at least one activity that benefited all four stakeholders. They were classified as accountable for activities that influenced significantly more external stakeholders than other internal stakeholders, even when activities influenced fewer than four external stakeholders. MAPPs were also accountable for significantly more activities recorded over the 12-month period than regulatory affairs, market access, commercial, and patient advocacy. CONCLUSIONS: This study generated and validated the first measure of MAPP value to pharmaceutical companies. MAPPs have unique value to pharmaceutical companies compared with other roles in terms of their accountability for activities that influence regulators, payors, prescribers, and patients. Through their accountability for pharmaceutical company activities and influence of external stakeholders, MAPPs play a key role in medicine adoption. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40290-021-00413-9. Springer International Publishing 2022-01-07 2022 /pmc/articles/PMC8818008/ /pubmed/34994965 http://dx.doi.org/10.1007/s40290-021-00413-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Jandhyala, Ravi
Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument
title Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument
title_full Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument
title_fullStr Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument
title_full_unstemmed Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument
title_short Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument
title_sort development and validation of the medical affairs pharmaceutical physician value (mappval) instrument
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818008/
https://www.ncbi.nlm.nih.gov/pubmed/34994965
http://dx.doi.org/10.1007/s40290-021-00413-9
work_keys_str_mv AT jandhyalaravi developmentandvalidationofthemedicalaffairspharmaceuticalphysicianvaluemappvalinstrument